NeuroPace $102 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Lannett Company $350 million senior secured notes offering
We advised the initial purchasers on the high-yield notes offering
Recursion Pharmaceuticals $500 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Diagnósticos da América R$3.3 billion equity offering
We advised the global coordinators and joint bookrunners on the Rule 144A / Regulation S offering
Ionis Pharmaceuticals $632.5 million convertible senior notes offering
We advised the purchasers on the Rule 144A convertible notes offering
Maravai LifeSciences $646.9 million secondary offering
We advised the joint book-running managers on the equity offering
Beam Therapeutics $300 million at-the-market offering
We advised the sales agent in connection with the equity offering
Alignment Healthcare $489.6 million IPO
We advised the underwriters on the IPO and Nasdaq listing
LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Gyroscope Therapeutics $148.0 million Series C equity financing
We advised Gyroscope Therapeutics on its private placement of preferred stock